3.0.0 377 2022-11-01T15:47:46Z 2022-11-01T15:47:46Z Senate S 2019-02-07 116 ssfi00 Finance Committee Senate Standing Referred to 2019-02-07T18:58:45Z Medicare Negotiation and Competitive Licensing Act of 2019 116 1046 HR 2019-09-25 Subcommittee Hearings Held. Related bill CRS 2019-02-07 ssfi00 Finance Committee Senate Read twice and referred to the Committee on Finance. IntroReferral 2019-02-07 Introduced in Senate IntroReferral 10000 9 Library of Congress B000944 Sen. Brown, Sherrod [D-OH] Sherrod Brown D OH N B001230 Sen. Baldwin, Tammy [D-WI] Tammy Baldwin D WI 2019-02-07 True K000367 Sen. Klobuchar, Amy [D-MN] Amy Klobuchar D MN 2019-02-07 True H001075 Sen. Harris, Kamala D. [D-CA] Kamala Harris D CA D. 2019-06-25 False W000817 Sen. Warren, Elizabeth [D-MA] Elizabeth Warren D MA A. 2019-10-31 False Health Competition and antitrust Drug safety, medical device, and laboratory regulation Health care costs and insurance Inflation and prices Licensing and registrations Manufacturing Medicare Prescription drugs Product safety and quality Public contracts and procurement Health 00 2019-02-07 Introduced in Senate 2019-07-26T20:26:29Z Medicare Negotiation and Competitive Licensing Act of 2019

This bill requires the Centers for Medicare & Medicaid Services (CMS) to negotiate with pharmaceutical companies regarding prices for drugs covered under the Medicare prescription drug benefit. (Current law prohibits the CMS from doing so.)

The CMS must take certain factors into account during negotiations, including the clinical- and cost-effectiveness of the drug, the financial burden on patients, and unmet patient needs. If the CMS is unable to negotiate the price of a drug, such drug is subject to competitive licensing in order to further its sale under Medicare, notwithstanding existing government-granted exclusivities.

Additionally, for one year after a drug is provided under a competitive license, such drug is also subject to specified price limitations; if the drug is not offered at such prices, the drug is subject to additional licensing that furthers its sale under any federal program (e.g., Medicaid).

]]> Medicare Negotiation and Competitive Licensing Act of 2019 Display Title Medicare Negotiation and Competitive Licensing Act of 2019 Short Title(s) as Introduced Medicare Negotiation and Competitive Licensing Act of 2019 Introduced in Senate IS Official Title as Introduced A bill to amend title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate prices of prescription drugs furnished under part D of the Medicare program. Introduced in Senate IS Introduced in Senate 2019-02-07T05:00:00Z https://www.govinfo.gov/content/pkg/BILLS-116s377is/xml/BILLS-116s377is.xml 2019-02-07 Read twice and referred to the Committee on Finance. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.